Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Operating Leases (2019 - 2025)

Wave Life Sciences' Operating Leases history spans 7 years, with the latest figure at $9.4 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 47.06% year-over-year to $9.4 million; the TTM value through Dec 2025 reached $9.4 million, down 47.06%, while the annual FY2025 figure was $9.4 million, 47.06% down from the prior year.
  • Operating Leases reached $9.4 million in Q4 2025 per WVE's latest filing, down from $11.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $33.7 million in Q3 2022 to a low of $9.4 million in Q4 2025.
  • Average Operating Leases over 5 years is $22.1 million, with a median of $23.6 million recorded in 2021.
  • Peak YoY movement for Operating Leases: crashed 49.04% in 2022, then surged 140.62% in 2023.
  • A 5-year view of Operating Leases shows it stood at $25.0 million in 2021, then rose by 28.7% to $32.1 million in 2022, then dropped by 20.9% to $25.4 million in 2023, then crashed by 30.07% to $17.8 million in 2024, then crashed by 47.06% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Operating Leases are $9.4 million (Q4 2025), $11.4 million (Q3 2025), and $13.6 million (Q2 2025).